The diagnostic workup for fibrocystic breast condition typically includes

The diagnostic workup for fibrocystic breast condition typically includes

• A. Ultrasound, mammography, and core-needle biopsy if suspicious
• B. Mastectomy and chemotherapy
• C. Fine-needle aspiration only
• D. MRI alone

Answer: (A)

In evaluating fibrocystic breast changes, the goal is to characterize findings with imaging and obtain tissue only if something looks suspicious. Ultrasound and mammography together provide complementary information: ultrasound helps distinguish cystic from solid lesions and guides aspiration or biopsy if needed, while mammography screens for calcifications and overall breast architecture that could raise concern. If a lesion appears suspicious on imaging or on physical exam—such as a solid, irregular mass or suspicious calcifications—a core-needle biopsy is performed to get a definitive histologic diagnosis and to rule out cancer. Mastectomy and chemotherapy are treatment modalities, not part of diagnosing fibrocystic changes. Fine-needle aspiration alone can sample cyst fluid but may miss solid lesions or fail to provide sufficient tissue architecture for a definitive diagnosis. MRI alone is not used as the initial diagnostic workup for fibrocystic changes; it’s reserved for problem-solving in specific situations or high-risk assessments, rather than routine evaluation.

In evaluating fibrocystic breast changes, the goal is to characterize findings with imaging and obtain tissue only if something looks suspicious. Ultrasound and mammography together provide complementary information: ultrasound helps distinguish cystic from solid lesions and guides aspiration or biopsy if needed, while mammography screens for calcifications and overall breast architecture that could raise concern. If a lesion appears suspicious on imaging or on physical exam—such as a solid, irregular mass or suspicious calcifications—a core-needle biopsy is performed to get a definitive histologic diagnosis and to rule out cancer.

Mastectomy and chemotherapy are treatment modalities, not part of diagnosing fibrocystic changes. Fine-needle aspiration alone can sample cyst fluid but may miss solid lesions or fail to provide sufficient tissue architecture for a definitive diagnosis. MRI alone is not used as the initial diagnostic workup for fibrocystic changes; it’s reserved for problem-solving in specific situations or high-risk assessments, rather than routine evaluation.